Resources - RESEARCH LITERACY
BPC-157 dosage, how it is taken and side effects: what the research does and does not show
BPC-157 has no human dose, because it has never completed a human trial. What the animal studies used, why oral and injected forms are both discussed, what side-effect data exist, what the FDA and WADA say, and why any "BPC-157 dosage" you read online is an extrapolation from rats.
BPC-157 does not have a dosage, in the sense that word normally carries. A dose is what a regulator approves after human trials establish what amount does what, at what risk. No completed human trial of BPC-157 has been published, it is not approved anywhere, and it has no licensed dose for any purpose. What exists is a body of animal research, mostly in rats, in which the compound was given at particular amounts by particular routes, and a large online literature that takes those amounts, scales them to a human body weight, and calls the result a protocol. This article explains what the research actually used, why oral and injected forms are both discussed, what is and is not known about side effects, what the American regulator and the anti-doping authorities have said, and how to read the claims you will meet. It is not a guide to taking anything.
What BPC-157 is
BPC-157 is a synthetic chain of fifteen amino acids. The name stands for Body Protection Compound; the sequence is reported to be derived from a protein found in human gastric juice by a research group at the University of Zagreb, led by Predrag Sikiric, who have published most of the literature on it since the early 1990s. In animal experiments it has been studied for effects on the healing of gut lining, tendon, ligament, muscle and bone, on blood vessel growth, and on a range of other systems. The breadth of claimed effects is itself unusual and is one reason independent researchers treat the literature cautiously: a compound reported to help almost everything invites the question of whether the experiments would detect it helping nothing.
What the animal studies actually used
Across the rat studies, the most frequently reported amount is around 10 micrograms per kilogram of body weight, with some experiments using 10 nanograms per kilogram and others higher. It has been given by injection under the skin, into muscle and into the abdominal cavity, by mouth dissolved in drinking water, and applied directly to wounds, skin and the eye, depending on what was being studied. Doses were typically given daily for days to weeks around an experimentally induced injury.
Three things about these figures matter for anyone trying to turn them into a human number. First, a rat is not a small human. Metabolic rate, drug handling, gut physiology and body-surface-to-mass ratios all differ, and simple weight scaling from rat to human is known to give wrong answers in both directions; regulators use more complex conversions and then still require human trials to confirm them. Second, the amounts were chosen to produce a measurable effect in an artificial injury model, not to be safe or effective in a person with a real one. Third, "10 micrograms per kilogram" appears online as though it were a settled human figure, which it has never been.
Injected or oral: what the research says and what it does not
Both routes appear in the animal literature. The Zagreb group has reported that BPC-157 is stable in human gastric juice for long periods, unlike most peptides, which are digested quickly, and they have used oral administration in drinking water in many rat experiments. On that basis, capsules and tablets are now sold alongside injectable vials.
What is missing is any controlled human study of either route. Nobody has measured how much of an oral dose reaches the bloodstream in people, whether it survives the human gut as it apparently survives gastric juice in a test tube, or whether an injected dose behaves in humans as it does in rats. The "oral versus injection" debate on forums is therefore a debate about which unproven route is better, conducted without the data that would settle it. The lesson on how dosing protocols are structured explains what a real answer to that question would need to contain.
Side effects: what is known and why "no side effects" is not reassurance
In the animal studies, adverse effects are rarely reported, and the developers have described the compound as having a wide safety margin in rats. Human data consist of user reports on forums and social media, which cannot establish safety: they are unverified, self-selected, and silent about people who had problems and did not post.
The absence of reported side effects in small animal studies is weak evidence. Such studies are not designed to detect harms, especially uncommon or delayed ones, and rats are poor sentinels for effects that matter in people. A compound that stimulates blood vessel growth and tissue proliferation, as BPC-157 is claimed to, raises theoretical concerns that only long-term human studies could address; none exist. In 2023 the US Food and Drug Administration placed BPC-157 in its category of bulk substances that may present significant safety risks when used in compounding, on the grounds that there are no human safety data to assess and the compound has not been studied for the routes people are using. It has since been removed from that category on a procedural basis, without any new safety data. That is a regulator saying plainly that the safety question is open, not answered.
What the FDA and WADA have said
The FDA's 2023 categorisation matters because compounding pharmacies in the United States had been preparing BPC-157 for patients under a legal grey area. It cited the lack of safety information, the potential for immune reactions to a peptide given by these routes, and the absence of any adequate human study. In 2026 BPC-157 was removed from that category when its nomination was withdrawn; it has not been added to the list of substances permitted for compounding, and the FDA has referred it to its compounding advisory committee for review. Its US compounding status is unsettled, not cleared.
The World Anti-Doping Agency includes BPC-157 in category S0 of its Prohibited List, which covers substances that have no current approval for human use by any regulator. It is banned in competition and out of it for athletes under anti-doping rules. Several national anti-doping bodies have issued warnings specifically naming BPC-157 because of its popularity in strength and endurance sport.
Regulatory status in the UK
BPC-157 is not a controlled drug in the UK and is not a licensed medicine. Supplying it for genuine laboratory research is not in itself prohibited, and it is widely sold on that basis, but whether a given sale is lawful depends on how the product is presented and what it is actually for, which the MHRA judges on overall impression. The moment a seller presents it as something for people to take, whether by describing injection schedules, promising recovery or healing, or selling it in a form designed for human use, it becomes an unauthorised medicinal product under the Human Medicines Regulations 2012, and selling or advertising it is an offence for the seller. The MHRA judges this on the overall impression a product gives, not on a disclaimer. Our article on whether peptides are legal in the UK covers the framework in detail.
The practical consequence for anyone reading a dosage page is this: a UK seller giving you a BPC-157 protocol is, by doing so, presenting a medicine they are not licensed to sell. The protocol is not clinical information. It is the marketing of an unauthorised product, and it should be read as such.
Why the dosage question cannot be answered honestly
Every legitimate dosing figure in medicine comes from the same sequence: phase 1 trials that establish safety and how the body processes the substance in people; phase 2 trials that find a dose range for a specific condition; phase 3 trials that confirm benefit and characterise harms in larger groups; regulatory review; and a licence that specifies strengths and a schedule. BPC-157 has not completed the first step. There is therefore no human dose, no maximum, no schedule, and no safety threshold, and anyone who supplies one is inventing it.
That is different from saying BPC-157 does nothing, or that it is dangerous. It is saying that nobody knows, because the work has not been done. Research literacy means holding that position even when a compound is interesting and the forum consensus is confident. The interest is real; the evidence is not yet.
How to read a BPC-157 claim
- Ask what species. If the study is in rats, that is where its conclusions live.
- Ask what was measured. Accelerated healing of a surgically induced tendon injury in a rat is a specific finding, not "heals tendons".
- Ask who funded and wrote it. Most of the literature comes from one research group; independent replication is thin.
- Ask whether a human dose is stated and where it came from. If it is a rat figure scaled by body weight, it is a guess.
- Ask whether the page selling you the protocol also sells the product. If so, you are reading an advertisement.
This article is educational content only and is not medical advice, diagnosis or a recommendation to use anything. BPC-157 is an unlicensed compound with no human clinical trial data; the amounts described are those used in animal experiments and are not instructions for use. Anyone with an injury or health concern should speak to a GP, physiotherapist or other qualified professional. Vivera Education sells nothing.
Frequently asked
- What is the BPC-157 dosage?
- There is none. No completed human clinical trial of BPC-157 has been published, it is not a licensed medicine anywhere, and no regulator has approved a dose. The figures quoted online are extrapolated from animal experiments, most often rat studies using around 10 micrograms per kilogram, and extrapolating a rat dose to a person is not a valid way to set a human dose.
- How is BPC-157 taken?
- In the published animal research it has been given by injection under the skin or into muscle, into the abdomen, by mouth in drinking water, and applied to the skin or eye, depending on the experiment. In people, there is no established route, because there is no established use. People who use products sold online report doing so on the basis of forum advice, not clinical guidance.
- Does oral BPC-157 work?
- The research group that developed BPC-157 reports that it is stable in gastric juice and has published rat studies in which it was given in drinking water. There are no controlled human studies of oral BPC-157, so whether capsules or tablets do anything in people is unknown. Claims that oral forms are proven are not supported by human evidence.
- What are the side effects of BPC-157?
- Unknown in humans, because the human safety studies have not been done. Animal studies report few adverse effects, but small animal studies are poor at detecting harms. In 2023 the US FDA placed BPC-157 in a category of compounding substances that may present significant safety risks, citing the lack of human safety data; in 2026 it was removed from that category after the nomination was withdrawn, without being approved for compounding. Reports from users are anecdotal and cannot establish either safety or harm.
- Is BPC-157 legal in the UK?
- It is not a controlled drug and is not a licensed medicine. Supplying it for genuine laboratory research is not in itself prohibited, but whether a given sale is lawful depends on how the product is presented and what it is actually for, which the MHRA judges on overall impression. Selling or advertising it for people to use makes it an unauthorised medicine, which is an offence for the seller. It is also prohibited in sport under the World Anti-Doping Agency list as a non-approved substance.
- Is BPC-157 banned by WADA?
- Yes. BPC-157 falls under category S0 of the WADA Prohibited List, which covers pharmacological substances with no current approval for human therapeutic use by any regulator. Athletes subject to anti-doping rules who use it risk a violation.
- Why do so many sites give a BPC-157 dose if there is not one?
- Because the question is searched constantly and the sites answering it are usually selling the product or funded by those who do. A figure taken from rat studies, scaled to human weight and presented as a protocol looks like information. It is a guess dressed as a dose, with no human data behind it.
- What would it take for BPC-157 to have a real dose?
- Phase 1 trials to establish safety and how the body handles it in people, then phase 2 and 3 trials for a specific condition, then regulatory review. None of that has been completed and, as of this writing, only small early-stage studies have been registered, with no results published.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.